Connect with us

Health

Experimental drug helps patients lose nearly a quarter of body weight in early trials

Published

on

Experimental drug helps patients lose nearly a quarter of body weight in early trials

NEWYou can now listen to Fox News articles!

An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials.

The drug, amycretin — developed by Novo Nordisk — works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is used in Ozempic and Wegovy to suppress appetite and boost insulin secretion.

“Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule,” Martin Holst Lange, executive vice president and head of development at Novo Nordisk, previously said in a statement sent to Fox News Digital.

GRANDFATHER’S SIMPLE CHANGES REVERSED PRE-DIABETES DIAGNOSIS THAT LEFT HIM ‘PETRIFIED’

Advertisement

In the study, which included 125 overweight or obese adults, participants who received weekly injections of amycretin lost more weight than those who took a placebo, according to a press release from Novo Nordisk.

Those who got the highest doses (up to 60 mg) lost up to 24.3% pounds after 36 weeks, compared to just 1.1% for the placebo group, per the release.

An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials. (iStock)

A previous phase 1 trial of the oral (pill) version of amycretin also showed that treatment was “safe and tolerable,” with an “observed reduction in body weight” compared to placebo, the company stated.

Taking the pill once a day led to around 10% weight loss, and those who doubled the dose lost 13%.

Advertisement

YOUR DNA COULD BE STOPPING YOU FROM LOSING WEIGHT, NEW STUDY SUGGESTS

Another benefit the researchers highlighted is that people taking amycretin did not appear to hit a “weight-loss plateau,” continuing to shed pounds as long as they took it.

“The lack of weight loss plateauing indicates the possibility of achieving further weight reductions with extended treatment,” Agnes Gasoirek, a senior clinical pharmacology specialist at Novo Nordisk, wrote in the phase 1 study findings.

Novo Nordisk presented the latest findings at the American Diabetes Association in Chicago on June 22. ((Photo by LISELOTTE SABROE/Scanpix Denmark/AFP via Getty Images))

Novo Nordisk presented the latest findings at the American Diabetes Association in Chicago on June 22; they were also published in the medical journal Lancet.

Advertisement

“We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk, in the release. 

“Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule.”

“These results reflect our robust pipeline in obesity, [and] our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals.”

The most common side effects of amycretin, similar to other GLP-1s, were gastrointestinal symptoms — primarily nausea, vomiting and decreased appetite.

Advertisement

Adverse events were “mild to moderate” in severity, according to researchers. More frequent doses resulted in greater side effects.

It’s important to monitor these side effects closely, experts advise, as GI issues are common among patients with obesity. 

“Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach,” a doctor said. (iStock)

“While the initial weight-loss outcomes are indeed encouraging, further studies are needed to ensure that the therapeutic benefits consistently outweigh the potential risks, especially with long-term administration,” Dr. Christine Ren-Fielding, director and chief of bariatric surgery at the NYU Langone Weight Management Program, previously told Fox News Digital.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Advertisement

While GLP-1-based drugs — including this new experimental pill — may show promising results, Ren-Fielding, who was not involved in the study, emphasized that they’re “not a cure-all for obesity.”

“Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach,” she said at the time.

For more Health articles, visit www.foxnews.com/health

“Pharmacological treatments can play a significant role in managing the condition, but they are often most effective when combined with other interventions.”

Next, Novo Nordisk plans to prepare for phase 3 trials of the medication, in both oral and injectable forms, for the management of obesity.

Advertisement

Health

Male fertility rates crash as doctors reveal health threats: ‘Something very wrong’

Published

on

Male fertility rates crash as doctors reveal health threats: ‘Something very wrong’

NEWYou can now listen to Fox News articles!

Scientists and physicians agree that there’s been a general decline in male fertility — but they aren’t sure why.

Social media buzz has pointed to a few environmental exposures as potential factors, including cellphones and electric vehicles.

But the reality is “more complicated” than that, according to experts who recently spoke to National Geographic.

ORIGIN OF DEADLY CANCER AFFECTING YOUNG ADULTS REVEALED IN ALARMING REPORT

Advertisement

Although it’s not clear whether the decline is at a stage where it should be considered a crisis, numbers show that overall fertility — demographically measured by the number of babies born compared to women of child-bearing age — has decreased.

Scientists and physicians agree that there’s been a general decline in male fertility. (iStock)

Dr. Alex Robles of the Columbia University Fertility Center in New York confirmed that clinical practitioners are “certainly seeing more couples where the male factor contributes to infertility.”

CELLPHONE HEALTH RISKS IN FOCUS OF NEW GOVERNMENT STUDY: ‘VERY CONCERNED’

“At least one-third of couples we evaluate have some male component,” he told Fox News Digital.

Advertisement

A 2017 meta-analysis published in Oxford Journals: Human Reproduction Update found that sperm counts in Western countries have declined by almost 60% globally since 1973. The 2023 update confirmed these same results.

Urologists can track declining fertility in sperm quality, while demographic data uses the number of babies born compared to women of child-bearing age as a benchmark, according to National Geographic. (iStock)

Lead study author and epidemiologist Hagai Levine warned that this trend could lead to human extinction if it isn’t addressed.

“This is the canary in the coal mine,” Levine, public health physician at the Hebrew University-Hadassah Braun School of Public Health, told National Geographic. “It signifies that something is very wrong with our current environment, as lower sperm counts predict morbidity and mortality.”   

DOCTORS WARN SOME POPULAR FOODS AND DRINKS COULD BE SECRETLY SABOTAGING MEN’S TESTOSTERONE LEVELS

Advertisement

These findings have been contradicted by other studies, however. A 2025 Cleveland Clinic analysis of studies from the last 53 years found sperm counts to be steady.

“There is no evidence to suggest that this decline is the cause of a precipitous decline in the ability to cause pregnancies,” primary study author Scott Lundy, a reproductive urologist at Cleveland Clinic, told National Geographic. “Most men, even with a modest decline in sperm counts, will still have no issues conceiving.”

Potential factors of decline

Multiple lifestyle factors can lead to a decline in male fertility, Robles noted, including obesity, smoking and diet, as well as environmental exposures and delayed parenthood.

National Geographic also reported that heavy drinking and marijuana use directly contribute to declining fertility and that quitting these habits, while also exercising and losing weight, can help.

Smoking of any kind can contribute to a decline in fertility, according to experts. (iStock)

Advertisement

Systemic inflammation, infection and disease can also have a “big, profound effect on the current status of fertility,” Lundy told National Geographic. 

Those who are getting over a fever from an infection, like the flu or COVID, will have a “drastically lower” sperm count for three months, he said.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Male infertility can also be a marker of overall health, according to Robles. “Poor semen parameters are associated with other medical conditions and may signal underlying metabolic, hormonal or environmental issues,” he told Fox News Digital.

Experts recommend seeing a doctor to discuss fertility concerns instead of relying on the internet. (iStock)

Advertisement

Allan Pacey, deputy dean of the Faculty of Biology, Medicine and Health at the University of Manchester, told National Geographic that the decline could be caused by increased use of contraception, as well as men waiting longer to have children or choosing not to have them at all.

CLICK HERE FOR MORE HEALTH STORIES

Microplastics have also been raised on social media as a potential culprit, but the effects are unclear, according to experts.

There is some evidence of endocrine-disrupting chemicals — which are substances found in reusable plastics and some disposable products — altering male fertility, Lundy revealed to National Geographic.

Myths busted

Concerns have circulated on social media that keeping a cellphone in a front pocket could harm male fertility. While Lundy said such an effect is biologically possible, there is currently no scientific evidence supporting the claim.

Advertisement

Another common myth is that infertility is mostly a women’s issue, Robles noted, but male factors contribute to about one-third to one-half of all cases.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The claim that taking supplements can boost sperm counts is another common myth, he said, adding that it’s not backed by strong scientific evidence.

“Men should focus on factors that we know matter: maintaining a healthy weight, avoiding tobacco, limiting alcohol and managing chronic health conditions,” Robles advised. 

One common myth is that infertility is mostly a women’s issue, but male factors contribute to about one-third to one-half of all cases. (iStock)

Advertisement

Experts recommend seeing a urologist to address fertility concerns. Robles said his approach begins with an evaluation, semen analysis, hormonal testing and medical history, while also exploring lifestyle factors.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

In addition to traditional treatment options, Robles said his fertility center also uses advanced tools that incorporate AI and robotics.

“Technologies like this are expanding options for patients who previously had very limited paths to biological parenthood,” he said.

Advertisement
Continue Reading

Health

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier

Published

on

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier


Advertisement





How To Curb Late-Night Cravings and Make Weight Loss Easier | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

Published

on

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

NEWYou can now listen to Fox News articles!

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge.

Advertisement

That’s according to new research from the University of California San Diego, which found that a specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk.

The researchers analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study in the late 1990s, according to the study’s press release. 

KEY FITNESS MEASURE IS STRONG PREDICTOR OF LONGEVITY AFTER CERTAIN AGE, STUDY FINDS

The women ranged from 65 to 79 years of age and showed no signs of cognitive decline at the start of the study.

After tracking the participants for up to 25 years, the researchers concluded that the biomarker phosphorylated tau 217 (p-tau217) was “strongly associated” with future mild cognitive impairment and dementia. 

Advertisement

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge. (iStock)

Women who had higher levels of p-tau217 at the beginning of the study were “much more likely” to develop the disease. The findings were published today in JAMA Network Open.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” first author Aladdin H. Shadyab, a UC San Diego associate professor of public health and medicine, told Fox News Digital. 

“These biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia.”

“Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin,” he added.

Advertisement

This long lead time could open the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life, according to Shadyab.

A specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk. (iStock)

“As the research advances, these biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia,” he said.

This risk relationship wasn’t the same across the board, however. Women over 70 with higher p-tau217 levels had “poorer cognitive outcomes” compared to those under 70, as did those with the APOE ε4 gene, which is a known risk factor for Alzheimer’s disease.

Advertisement

The study also found that p-tau217 was a stronger predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy compared to those who received a placebo.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” said senior author Linda K. McEvoy, senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, in the release. 

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” a researcher said. (iStock)

“This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Advertisement

Blood tests for Alzheimer’s disease are still being studied and are not recommended for routine screening in people without symptoms, Shadyab noted. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

More research is needed before this approach can be considered for clinical use prior to cognitive symptoms. 

Future studies should investigate how other factors — like genetics, hormone therapy and age-related medical conditions — might interact with plasma p-tau217, the researchers added.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

“The study examined only older women, so the findings may not necessarily apply to men or younger populations,” Shadyab noted. “We also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.”

Continue Reading

Trending